Harvest One Cannabis Inc (CVE:HVT) (OTCQX:HRVOF) said Wednesday that its wholly-owned subsidiary Satipharm Ltd has expanded its product offerings to include two new variants of its unique proprietary CBD Gelpell product, further enhancing its product portfolio currently on sale in major retailers and pharmacy chains throughout the United Kingdom and Ireland.
In a statement, the Vancouver-based company said the new Satipharm CBD advanced range products combine CBD with specifically selected vitamins in the company's proprietary Gelpell capsules. The patented Gelpell technology delivers CBD in “seamless microbeads that are clinically proven to increase bioavailability,” noted the company.
The new advanced range offers two variants, Focus and Active, designed to address specific consumer's needs:
- Active: Satipharm CBD Advanced Active combines CBD with vitamins A, D, E and K to support general body health and movement
- Focus: Satipharm CBD Advanced Focus combines CBD with B vitamins to support mental wellbeing
Harvest One Cannabis CEO Andy Bayfield pointed out that “a differentiated product offering” is key to building a successful brand, as the company continues to expand its distribution with retailers and pharmacy chains in the United Kingdom and Ireland.
"These innovative new product variations, Active and Focus offer our consumers solutions to specific needs, while leveraging our proven Gelpell delivery technology," Bayfield said.
Satipharm's suite of products now includes its flagship product - a 10 mg CBD Gelpell capsule, a high-strength 50 mg CBD Gelpell capsule and the CBD advanced range Focus and Active variants. It also includes Satipharm's range of Lemon & Lime and Cinnamon flavoured CBD oils providing a differentiated market offering to satisfy a larger consumer base.
Manufactured in Switzerland and GMP-certified, every Gelpell capsule delivers a “consistent dose of cannabinoids,” the company noted, while also pointing out that Satipharm CBD Gelpell capsules have “3.5 times higher bioavailability compared to standard CBD oils.”
The capsules have undergone Stage I and Stage II clinical trials with the results published in two peer-reviewed international medical journals.
Harvest One serves as an umbrella over three wholly-owned subsidiaries: United Greeneries, which is a licensed cannabis producer; Satipharm, which develops cannabis-based health products; and Dream Water, which offers consumer sleep aids.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive